newsfilter
← Latest News
ACCESS Newswire·

Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients With Chronic Graft-Versus-Host Disease

- FDA Grants Priority Review and Sets PDUFA Date of May 30, 2021 - - Application Being Evaluated Under FDA's Real-Time Oncology Review (RTOR) and Project Orbis Pilot Programs -